BioAge Labs will host an R&D Day webcast on May 8, 2026, to present Phase 1 clinical data for BGE-102, a novel oral NLRP3 inflammasome inhibitor. The drug targets inflammation linked to atherosclerotic cardiovascular disease and retinal diseases like diabetic macular edema. The event will feature presentations by BioAge leadership and four medical experts discussing the drug's mechanism and therapeutic potential. Phase 2 data for cardiovascular risk is expected in the second half of 2026, with retinal disease data anticipated in mid-2027.
Hope Bancorp, Inc. reported Q2 2026 earnings per share of $0.27, surpassing the expected $0.26 and up from $0.19 last year, indicating improved profitability. The company also exceeded revenue forecasts with $147.82 million versus the estimated $146....
UDR, Inc. is set to report Q2 2026 earnings with analysts projecting $0.13 per share on $423.35 million revenue, reflecting a 1.6% year-over-year earnings decline. Despite this, UDR anticipates sequential growth in adjusted funds from operations (FFO...
Joe Cicero, Chief Marketing Officer at Security Risk Advisors, has been named a finalist in the 2026 CRN Best of the Channel Awards for Best Channel Visionary of the Year. He is recognized for unifying marketing, alliances, and sales into a partner-l...
Eneba, a fast-growing digital entertainment marketplace, has partnered with NetEase Games to become an official distributor of NetEase Pay gift cards worldwide. This allows users to buy gift cards in various USD denominations with instant delivery, r...
The Law Offices of Frank R. Cruz announced class action lawsuits against AeroVironment (AVAV), Calix (CALX), Zoetis (ZTS), and Lucid Group (LCID) for allegedly making false or misleading statements and withholding material adverse information about t...
